Clinical aspects and risk factors of lupus nephritis: a retrospective study of 156 adult patients

Fang Yuan1,*, Fenghua Wei2,*, Junjie Wang1,* and Yanwu You1

Abstract

Objective: To analyze the clinical manifestations, laboratory indexes, disease activity, and pathological types of lupus nephritis (LN) in adult patients.

Methods: We retrospectively analyzed the clinical manifestations, laboratory indexes, and pathological classifications of 156 adult patients first diagnosed with LN between July 2013 and November 2017. Patients were categorized according to the following criteria: active or inactive LN, LN with or without renal damage, and mild or severe LN.

Results: Immunoglobulin G and A levels, 24-hour proteinuria, and anti-dsDNA, anti-Sm, and anti-ribosomal P protein antibody positivity rates were all significantly increased in patients with active LN compared with inactive LN. Anti-dsDNA antibody positivity and 24-hour proteinuria were significantly increased, whereas hemoglobin, serum albumin, and C3 and C4 levels were significantly decreased in patients with LN and renal damage compared with those without renal damage. Anti-dsDNA and anti-Sm antibody positivity rates and 24-hour proteinuria were significantly increased, while hemoglobin, serum albumin, C3 and C4 levels, and estimated glomerular filtration rate were significantly decreased in patients with severe LN compared with patients with mild LN.

Conclusions: LN can display various clinical manifestations, laboratory indexes, levels of disease activity, and pathological types in adult patients.

1Department of Nephrology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, People’s Republic of China
2Department of Outpatients, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, People’s Republic of China

*These authors contributed equally to this work.

Corresponding author:
Yanwu You, Department of Nephrology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise 533000, Guangxi, People’s Republic of China.
Email: youyanwu@163.com
Keywords
Systemic lupus erythematosus, clinical analysis, lupus nephritis, pathogenesis, disease activity, renal damage

Date received: 7 February 2019; accepted: 2 August 2019

Introduction
Systemic lupus erythematosus (SLE) is a diffuse autoimmune-mediated connective tissue disease mainly manifested by immune inflammation, involving multiple systems and organs. Previous studies showed that approximately 50% of patients with SLE experience renal damage, and histopathological studies confirmed that 100% of patients with SLE had varying degrees of renal pathological changes. Lupus nephritis (LN) is the most severe form of organ damage in patients with SLE and one of the most common secondary glomerular diseases, accounting for approximately 70% of secondary glomerular diseases based on histopathological examination. Importantly, LN frequently remains unrecognized until it has developed into full-blown nephritic and/or nephrotic syndrome with renal failure.

Changes in several indicators, including the presence or increase of protein in the urine, positive autoantibodies, and decreased hemoglobin and complement levels, may reflect SLE disease activity and renal damage. However, the sensitivity and specificity of these indicators and their relationships with clinical manifestations remain controversial. The associations between these indicators and disease activity, renal damage, and pathological lesions, and their clinical relevance thus remain unclear.

In this retrospective study, we analyzed the clinical and laboratory data for 156 patients with LN and analyzed the relationships among disease characteristics, including disease activity, degree of renal damage, and severity of pathological type.

Patients and methods

Subjects
Adult patients initially diagnosed with LN at the Affiliated Hospital of Youjiang Medical University for Nationalities between July 2013 and November 2017 were included in this study. All patients fulfilled the Systemic Lupus International Collaborating Clinics 2012 classification criteria for SLE. Patients were excluded if they had rheumatoid arthritis, skin inflammation, systemic sclerosis, nodular polyarteritis, epilepsy, organic brain disease, psychosis, idiopathic thrombocytopenic purpura, or a primary glomerular disease. The study protocol was approved by the ethics committee of Affiliated Hospital of Youjiang Medical University for Nationalities. Written informed consent was obtained from each patient. The study was conducted in accordance with the principles of the Declaration of Helsinki.

Diagnostic criteria
Disease activity was evaluated according to the SLE disease activity index 2000 (SLEDAI-2K). Patients fulfilling any of the following criteria were diagnosed with LN: 24-hour urine protein level >0.5 g or +++; tubules (erythrocyte tubules, granulotubules, or mixed tubules) and/or renal dysfunction (according to the pathological classification standard established by International Society of Nephrology/Renal Pathology Society in 2003 and the National Institutes of Health pathological index of lupus nephritis); and abnormal renal biopsy.
The pathological classification standard established by the International Society of Nephrology/Renal Pathology Society in 2003 was used for pathological classification of LN.

The following features were considered as clinical manifestations of LN: simple hematuria (gross or microscopic hematuria without proteinuria); simple proteinuria (proteinuria without hematuria); hematuria and proteinuria (main manifestations of hematuria and proteinuria); nephrotic syndrome (heavy proteinuria ≥3.5 g/24 hour, hypoproteinemia ≤30 g/L, hyperlipemia, and edema); and renal dysfunction (significantly increased blood urea nitrogen and creatinine, accompanied by anemia, hypertension, and edema).

Groups

All patients with LN were divided into the following subgroups: active LN (SLEDAI-2K score >10) and inactive LN (score ≤10); LN with renal damage (estimated glomerular filtration rate [eGFR] < 60 mL/minute) and without renal damage (eGFR ≥60 mL/minute), according to patients’ renal function; and mild LN (pathological class I–II) and severe LN (pathological class III–V).

Data acquisition

Peripheral blood samples were obtained from patients with LN and fasting venous blood was obtained from all patients in the morning. The following laboratory data were recorded: hemoglobin level, white blood cell count, blood platelet count, routine urine analysis, serum albumin level, 24-hour proteinuria, immunoglobulin level, serum C3 and C4, autoantibodies (anti-dsDNA, anti-Sm, anti-U1RNP, antiribosomal P protein (anti-Rib), anti-SSA, anti-SSB, and anti-Scl-70), pathological classification results, and clinical data.

Statistical analysis

All statistical analyses were carried out using SPSS for Windows, Version 21.0 (IBM Corp., Armonk, NY, USA). Quantitative variables were expressed as mean ± standard deviation. Non-parametric distribution data were expressed as median and interquartile range. Quantitative variables were compared using t-tests and non-parametric variables using χ² tests. All tests were two-tailed, and a P value < 0.05 was considered statistically significant. Patients with missing data were excluded.

Results

Clinical features of patients with LN

A total of 156 adult patients (136 women, 20 men; mean age 38.09 ± 14.98 years, range 18–80 years) were included in the study. The sex ratio was 6.8:1 (87.18% women, 12.82% men). The mean age of the women was 37.35 ± 14.32 years and that of the men was 41.86 ± 17.71 years. Hematological abnormalities were the most common clinical manifestations (76.28%), followed by arthritis (57.69%), malar rash (50.64%), serositis (36.54%), photosensitization (15.38%), and oral ulcers (10.90%). Renal pathology was class I in 19 cases (12.18%), class II in 20 cases (12.82%), class III in 29 cases (18.59%), class IV in 62 cases (39.74%), and class V in 26 cases (16.67%).

Comparison of clinical manifestations and laboratory parameters between patients with active and inactive LN

A total of 132 patients (84.62%) had active LN and 24 (15.38%) had inactive LN. The main clinical manifestations of active LN were hematological abnormalities (80.30%), arthritis (62.12%), serositis (37.88%), malar rash (32.58%), photosensitization (11.36%),
and oral ulcers (6.82%) (Table 1). The incidences of arthritis, photosensitization, and hematological abnormalities and the rates of anti-dsDNA antibody, anti-Sm antibody, and anti-Rib antibody positivity were significantly higher in patients with active LN compared with those with inactive LN (all $P < 0.05$). However, oral ulcers were significantly less frequent in patients with active (6.82%) compared with inactive LN (33.33%).

Immunoglobulin G (IgG) and IgA levels and 24-hour proteinuria were significantly increased, while hemoglobin, serum albumin, C3 and C4 levels, and eGFR were significantly decreased in patients with active LN compared with those with inactive LN ($P < 0.05$) (Table 2).

### Table 1. Comparison of clinical manifestations and antibodies between patients with active and inactive LN.

| Clinical manifestation or antibodies | Number (rate%) | Active LN | Inactive LN | $\chi^2$ value | $P$ value |
|-------------------------------------|----------------|-----------|-------------|----------------|-----------|
| Arthritis                          | 90 (57.69)     | 82 (62.12) | 8 (33.33)   | 6.895          | 0.009     |
| Photosensitization                 | 24 (15.38)     | 15 (11.36) | 9 (37.50)   | 8.743          | 0.003     |
| Malar rash                          | 49 (30.64)     | 43 (32.58) | 6 (25.00)   | 0.541          | 0.462     |
| Neuropsychiatric disorders         | 9 (5.77)       | 7 (5.30)   | 2 (8.33)    | 0.012          | 0.913     |
| Oral ulcer                          | 17 (10.90)     | 9 (6.82)   | 8 (33.33)   | 12.100         | 0.001     |
| Hematological abnormality           | 119 (76.28)    | 106 (80.30) | 13 (54.17)  | 7.667          | 0.006     |
| Serositis                           | 58 (36.54)     | 50 (37.88) | 8 (33.33)   | 0.180          | 0.672     |
| Anti-ds DNA                         | 78 (50.00)     | 73 (55.30) | 5 (20.83)   | 9.652          | 0.002     |
| Anti-U1RNP                          | 66 (42.31)     | 55 (41.67) | 11 (45.83)  | 0.144          | 0.704     |
| Anti-Sm                             | 101 (64.74)    | 94 (71.21) | 7 (29.17)   | 15.728         | <0.001    |
| Anti-SSA                            | 117 (75.00)    | 99 (75.00) | 18 (75.00)  | 0.000          | 1.000     |
| Anti-SSB                            | 41 (26.28)     | 35 (26.52) | 6 (25.00)   | 0.024          | 0.877     |
| Anti-Rib                            | 75 (44.08)     | 72 (54.55) | 3 (12.50)   | 14.381         | <0.001    |
| Anti-Scl-70                         | 4 (2.56)       | 3 (2.27)   | 1 (4.17)    | 0.000          | 1.000     |

$\#P < 0.05$ compared with inactive LN. LN, lupus nephritis.

### Table 2. Comparison of routine laboratory parameters between patients with active and inactive LN.

| Variable                          | Active LN       | Inactive LN    | t/Z value | $P$ value |
|-----------------------------------|-----------------|----------------|-----------|-----------|
| Hemoglobin (g/L)                  | 96.04 ± 23.25\# | 106.46 ± 23.27 | 2.019     | 0.045     |
| Leukocytes ($\times 10^9$/L)      | 4.95 (3.30, 7.33)| 6.05 (5.33, 7.55)| -1.901   | 0.057     |
| Thrombocytes ($\times 10^9$/L)    | 197.42 ± 100.98 | 205.33 ± 84.44 | 0.361     | 0.718     |
| Albumin (g/L)                     | 28.95 ± 8.04\#  | 33.94 ± 8.24   | 2.788     | 0.006     |
| Creatinine clearance rate (mL/minute) | 53.67 (41.90, 70.25) | 77.32 (56.18, 101.50) | -3.592 | <0.001 |
| eGFR (mL/minute)                  | 57.49 (34.88, 76.03) | 75.09 (50.71, 96.12) | -2.379  | 0.017     |
| 24-h proteinuria (g/24 h)         | 1.55 (0.44, 3.19)\# | 0.16 (0.06, 0.31) | -4.868    | <0.001    |
| C3 (mg/mL)                        | 38.40 (21.15, 51.00)\# | 97.50 (72.75, 115.53) | -5.877    | <0.001    |
| C4 (mg/mL)                        | 6.60 (3.25, 14.88)\# | 13.60 (6.55, 25.75) | -2.945    | 0.003     |
| IgG (g/L)                         | 18.17 ± 8.90\#  | 12.26 ± 7.83   | -3.045    | 0.003     |
| IgA (g/L)                         | 2.87 ± 1.22\#   | 1.97 ± 1.56    | -3.168    | 0.002     |
| IgM (g/L)                         | 1.27 (0.79, 1.82)\# | 0.97 (0.79, 1.54) | -1.820    | 0.069     |

Values given as mean ± standard deviation or median (interquartile range). $\#P<0.05$ compared with inactive LN. LN, lupus nephritis; eGFR, estimated glomerular filtration rate.
Comparison of clinical manifestations and laboratory parameters between patients with LN with and without renal damage

Ninety-nine patients (63.46%) with LN had renal damage and 57 patients (36.54%) did not. The main clinical manifestations of LN with renal damage were hematological abnormalities (93.94%), arthritis (79.80%), serositis (49.49%), malar rash (33.33%), photosensitization (13.13%), and oral ulcers (10.10%) (Table 3). The incidences of arthritis, hematological abnormalities, and serositis, and anti-dsDNA antibody positivity were increased in patients LN with renal damage compared with those without renal damage ($P < 0.05$).

The level of 24-hour proteinuria was significantly increased, whereas hemoglobin, serum albumin, and C3 and C4 levels were significantly decreased in patients with LN with renal damage compared with those without renal damage ($P < 0.05$) (Table 4).

Comparison of clinical manifestations and laboratory parameters between patients with mild and severe LN

Thirty-nine patients (25.00%) had mild LN and 117 patients (75.00%) had severe LN. The various intrarenal manifestations included simple hematuria (25/156, 16.03%), simple proteinuria (56/156, 35.90%), hematuria combined with proteinuria (76/156, 48.72%), nephrotic syndrome (36/156, 23.08%), and renal failure (25/156, 16.03%) (Table 5). The main extrarenal manifestations in patients with severe LN were hematological abnormalities (76.92%), arthritis (62.39%), serositis (39.32%), malar rash (33.33%), photosensitization (11.97%), and oral ulcers (10.26%). The incidences of hematuria combined with proteinuria, nephrotic syndrome, renal failure, arthritis, photosensitization, and anti-dsDNA antibody and anti-Sm antibody positivity were increased in patients with severe LN compared with those with mild LN ($P < 0.05$).

Table 3. Comparison of clinical manifestations and antibodies between patients with LN with and without renal damage.

| Clinical manifestation or antibodies | Number (rate%) | LN with renal damage | LN without renal damage | $\chi^2$ value | $P$ value |
|------------------------------------|----------------|---------------------|------------------------|----------------|-----------|
| Arthritis                          | 90 (57.69)     | 79 (79.80)$^\#$    | 11 (19.30)             | 54.244         | $<0.001$  |
| Photosensitization                 | 24 (15.38)     | 13 (13.13)          | 11 (19.30)             | 1.057          | 0.304     |
| Malar rash                         | 49 (50.64)     | 33 (33.33)          | 16 (28.07)             | 0.465          | 0.495     |
| Neuropsychiatric disorders         | 9 (5.77)       | 5 (5.05)            | 4 (7.02)               | 0.257          | 0.612     |
| Oral ulcer                         | 17 (10.90)     | 10 (10.10)          | 7 (12.28)              | 0.177          | 0.674     |
| Hematological abnormality          | 119 (76.28)    | 93 (93.94)$^\#$    | 26 (45.61)             | 46.691         | $<0.001$  |
| Serositis                          | 58 (36.54)     | 49 (49.49)$^\#$    | 9 (15.79)              | 17.595         | $<0.001$  |
| Anti-dsDNA                         | 78 (50.00)     | 57 (57.58)$^\#$    | 21 (36.84)             | 6.220          | 0.013     |
| Anti-U1RNP                         | 66 (42.31)     | 40 (40.40)          | 26 (45.61)             | 0.402          | 0.526     |
| Anti-Sm                            | 101 (64.74)    | 67 (67.68)          | 34 (59.65)             | 1.021          | 0.312     |
| Anti-SSA                           | 117 (75.00)    | 75 (75.76)          | 42 (73.68)             | 0.083          | 0.773     |
| Anti-SSB                           | 41 (26.28)     | 27 (27.27)          | 14 (24.56)             | 0.137          | 0.711     |
| Anti-Rib                           | 75 (44.08)     | 52 (52.53)          | 23 (40.35)             | 2.148          | 0.143     |
| Anti-Scl-70                        | 4 (2.56)       | 2 (2.02)            | 2 (3.51)               | 0.321          | 0.571     |

$^\#P < 0.05$ compared with LN without renal damage. LN, lupus nephritis.
The level of 24-hour proteinuria was significantly increased, whereas hemoglobin, serum albumin, C3 and C4 levels, and eGFR were significantly decreased in patients with severe LN compared with those with mild LN (Table 6) \( (P < 0.05) \).

**Discussion**

SLE is characterized by the production of multiple autoantibodies that form an immune complex, which is the main pathogenic factor of the disease. LN is a renal
A disease associated with high mortality, characterized by severe organ damage in patients SLE. It is difficult to determine the activity status of LN and the associated renal damage because of the diversity and complexity of the clinical manifestations of SLE. However, evaluating disease activity, the degree of renal damage, and the relationships between renal pathology and laboratory indicators is essential to improve treatment protocols and prognosis.

Previous studies showed that women accounted for the majority of SLE cases, with a female: male ratio of approximately 7:1 to 9:1.8,9 The ratio in the current study was 6.8:1, which was similar to that reported by Boodhoo et al.10 (6.5:1). Hematological abnormalities are the most common clinical manifestations of LN. Hemocytosis typically occurs in SLE with clinical manifestations including anemia, leukopenia, and thrombocytopenia, which can easily be misdiagnosed as blood system diseases. However, the hematological abnormalities in SLE are generally believed to be related to immunological abnormalities.11 The current study demonstrated correlations between hematological abnormalities and disease activity and renal damage, consistent with previous results.12

Anemia is the most common hematological abnormality in patients with SLE. This may be related to the presence of autoantibodies, which were previously found in bone marrow hematopoietic cells and erythrocytes in patients with SLE, resulting in pancytopenia or anemia.13 Alternatively, the anemia may be caused by a combination of erythropoietin deficiency and anti-erythropoietin antibodies.14,15

The incidences of arthritis and photosensitization in the present study were 57.69% and 15.38%, respectively, which were lower than previously reported.16 This apparent discrepancy could be because the subjects underwent renal biopsy and therefore had limited movement.

A previous study reported that nephrotic syndrome was the main clinical phenotype in patients with severe LN,17 as a result of severe Sertoli cell damage.18 Nephrotic syndrome in LN is usually non-simple and combined with hematuria and even renal failure.19

The current study found no significant differences in IgG, IgA, and IgM levels between patients with LN with and without renal damage, and between patients with mild and severe LN. However, the mean immunoglobulin levels were lower in

### Table 6. Comparison of routine laboratory parameters between patients with mild and severe LN.

| Variable          | Mild LN       | Severe LN      | t/Z value | P value |
|-------------------|---------------|----------------|-----------|---------|
| Hemoglobin (g/L)  | 114.36 ± 20.57| 92.07 ± 21.75* | 5.617     | <0.001  |
| Leukocyte (x 10^9/L) | 5.30 (3.60, 7.80) | 5.30 (3.35, 7.05) | -0.483 | 0.629   |
| Thrombocyte (x 10^9/L) | 192.15 ± 84.98 | 200.80 ± 102.75 | -0.474 | 0.636   |
| Albumin (g/L)     | 35.69 ± 8.59  | 27.73 ± 7.12*  | 5.735     | <0.001  |
| eGFR (mL/minute)  | 84.96 (73.69, 96.12) | 53.07 (33.05, 68.73)* | -6.965 | <0.001  |
| 24-h proteinuria (g/24 h) | 0.23 (0.08, 2.61) | 1.51 (0.40, 2.91)* | -2.963 | 0.003   |
| C3 (mg/mL)        | 60.00 (41.00, 104.00) | 36.00 (20.55, 51.00)* | -4.541 | <0.001  |
| C4 (mg/mL)        | 17.00 (11.00, 27.00) | 6.00 (3.05, 13.10)* | -4.943 | <0.001  |
| IgG (g/L)         | 15.80 ± 8.09  | 17.75 ± 9.24   | -1.176    | 0.242   |
| IgA (g/L)         | 2.81 ± 1.42   | 2.70 ± 1.28    | 0.440     | 0.660   |
| IgM (g/L)         | 1.25 (0.85, 1.82) | 1.23 (0.79, 1.73) | -0.061 | 0.951   |

Values given as mean ± standard deviation or median (interquartile range). *P < 0.05 compared with mild LN. LN, lupus nephritis; eGFR, estimated glomerular filtration rate.
patients with LN with renal damage and in patients with severe LN. This may be due to large amounts of immunoglobulins being deposited in the glomerulus in patients with LN with renal damage and those with severe LN, resulting in decreased serum immunoglobulin levels.

Although there are several criteria for assessing the activity of SLE, no gold standard has yet been established. Immune complexes are widely accepted to play an important role in the progression of kidney disease in LN. Furthermore, some previous studies suggested that serum IgG, C3, and C4 levels were associated with disease activity in SLE, while others reported that decreased serum C4 level was not closely related to disease activity in SLE. A correlation between hypo-complementemia and active LN has been reported, with normal complement levels associated with stable renal function, while long-term hypo-complementemia could lead to deteriorating renal function. In the present study, C3 and C4 levels were significantly decreased in patients with LN with renal damage compared with those without renal damage, and in patients with severe LN compared with patients with mild LN. These findings were similar to those of our previous study. This suggests that patients with LN and renal damage were more prone to hypo-complementemia, indicating that lower serum complement levels were associated with more severe pathological lesions.

Anti-dsDNA antibodies are exclusive to patients with SLE and thus represent an SLE-specific antibody. Numerous studies have demonstrated correlations between anti-dsDNA antibody levels and clinical manifestations, illness severity, and disease activity, suggesting a potential role in assessing patient condition and prognosis. Renal damage usually occurs in the active stage of the disease, and anti-dsDNA antibodies were found to play an important pathogenic role and to be a risk factor for LN. Consistent with this finding, 55.56% of patients with LN with anti-dsDNA antibodies in the present study had renal damage.

Several studies have found no correlation between anti-dsDNA antibody levels and the presence and severity of renal damage. Recent studies found that 30% of patients with LN were negative for anti-dsDNA antibodies, while 25% of patients with SLE were positive for anti-dsDNA antibodies but did not have LN. In the current study, 36.84% of patients were positive for anti-dsDNA antibodies but did not have renal damage. Further studies are therefore needed to explore the role of pathogenic antibodies in the injury mechanism of LN. Nucleosomes and their antibody molecules have also become increasingly significant in the pathogenesis of LN. Napirei et al. found that the activity of anti-dsDNA antibodies disappeared after removal of the nucleosomes and their antibody molecules, suggesting that these may mediate the binding of antigens, possibly initiating the pathological process of LN. The severity of LN should thus be assessed based on the level of organ damage rather than on antibody levels. Further studies are needed to clarify the relationship between anti-dsDNA antibodies and renal damage.

The rate of anti-Sm antibody positivity in patients with SLE is 10% to 30%. Although the detection rate is low (30%–40%), the specificity is as high as 92.2% to 99%, and anti-Sm antibody positivity is thus included in the diagnostic criteria for SLE. The anti-Sm positivity rate in the current study was 64.74%. Although the relationship between anti-Sm antibodies and disease activity remains controversial, the current study demonstrated that anti-Sm antibodies were a major indicator of disease activity. Furthermore, previous studies showed that the incidence of renal damage was higher in patients with SLE who were
positive for anti-Sm antibodies compared with those without anti-Sm antibodies, especially in patients who were also positive for anti-dsDNA antibodies. Consistently, the anti-Sm antibody positivity rate in the present study was significantly increased in patients with severe LN compared with patients with mild LN, suggesting that anti-Sm antibodies are associated with LN as well as its pathological lesions, and that higher anti-Sm antibody titers correlate with more severe pathological lesions.

Anti-U1RNP antibody is an essential serological indicator for the diagnosis of mixed connective tissue disease. The positivity rate for anti-U1RNP in SLE is 30% to 40%, but it may also be positive in other rheumatoid diseases, and its specificity is therefore not high. Previous studies showed a higher incidence of renal damage in patients with SLE who were positive for anti-U1RNP antibodies compared with those who were negative. However, the current study did not identify anti-U1RNP antibodies as a factor affecting disease activity, renal damage, or pathological lesions.

Anti-Rib antibody mainly targets P0, P1, and P2, which comprise the cytoplasmic subunit of phosphoric acid protein. Its positivity rate in SLE is 14.0% to 22.0% and its specificity is high, with patients positive for anti-Rib antibody often having neurological damage. Moreover, anti-Rib antibodies are often present throughout the duration of SLE, and their degradation is similar to that of anti-dsDNA antibodies, except that they do not disappear immediately with remission of the disease. In addition, the anti-Rib positivity rate was significantly higher in the cerebrospinal fluid of patients with SLE and diffuse psychiatric syndromes compared with those with neurological syndromes or peripheral neuropathy, as well as in those with non-inflammatory neurological disease. However, other reports found no association between anti-Rib antibodies and SLE neurological damage. Anti-Rib antibodies were also shown to be correlated with disease activity, and their positivity rate and titer were significantly increased in patients with active SLE. Some studies have suggested that anti-Rib antibodies and LN are closely related, while other studies found that the correlation was more significant when both anti-Rib and anti-dsDNA antibodies were present, compared with either antibody alone. Although anti-Rib antibody levels were not related to renal damage or pathological lesions in the present study, anti-Rib antibody was suggested to be a factor affecting disease activity. Nevertheless, more studies are required to explore the mechanism underlying the role of anti-Rib antibody in patients with LN.

The rate of anti-SSA antibody positivity in patients with SLE was 30% to 50% and that of anti-SSB antibody was 10% to 15%, with higher positivity rates in patients with active compared with inactive SLE. Few patients with LN had both types of antibodies or only anti-SSB antibodies, whereas anti-SSA antibodies alone were detected in many patients. Neither anti-SSA nor anti-SSB antibodies were found to affect disease activity, renal damage, or pathological lesions in the present study.

The clinical manifestations and laboratory parameters differed among the groups in the current study. Clinicians need to evaluate disease activity, the degree of renal damage, and the severity of the pathological lesions to develop a reasonable therapeutic strategy for LN. This requires an analysis of the clinical manifestations and laboratory indicators of LN, especially when renal biopsy cannot be performed for various reasons.

The main limitation of this study was the lack of a prospective design in terms of the correlations between the various indicators and treatment and prognosis.
In conclusion, the results of this study suggest that increased 24-hour proteinuria and IgG level, decreased C3, hemoglobin level, and eGFR, and the presence of anti-Sm and anti-dsDNA antibodies are involved in the pathogenesis of LN in adult patients. For patients who cannot undergo renal biopsy for various reasons, observation of their clinical manifestations and analysis of laboratory indicators can help to evaluate the activity of LN, the degree of renal function damage, and the severity of pathological damage, to allow the development of a reasonable diagnosis and treatment plan.

Acknowledgements
The authors would like to thank Editage for editing the manuscript.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This study was supported by grants from the National Natural Science Foundation of China (Nos. 81560271 and 81860296) and the Natural Science Foundation of Guangxi (Nos. 2017GXNSFAA198005 and 2018GXNSFAA281038).

ORCID iD
Yanwu You https://orcid.org/0000-0002-2612-5317

References
1. Bakr A, Laimon W, El-Ziny MA, et al. The emergence of systemic lupus erythematosus in hypothyroid patients: two case reports and mini review. Lupus 2014; 23: 825–828.
2. Seshan SV and Jennette JC. Renal disease in systemic lupus erythematosus with emphasis on classification of lupus glomerulonephritis: Advances and implications. Arch Pathol Lab Med 2009; 133: 233–248.
3. Jeganathan J, Kumar S, Khalid M, et al. Pattern of glomerular diseases in a tertiary care center in South India: a prospective study. Saudi J Kidney Dis Transpl 2013; 24: 168–171.
4. Contreras G, Roth D, Pardo V, et al. Lupus nephritis: a clinical review for practicing nephrologists. Clin Nephrol 2002; 57: 95–107.
5. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.
6. Gladman DD, Ibañez D and Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291.
7. Avihingsanon Y and Hirankarn N. Major lupus organ involvement: severe lupus nephritis. Lupus 2010; 19: 1391–1398.
8. Connolly JJ and Hakonarson H. Role of cytokines in systemic lupus erythematosus: Recent progress from GWAS and sequencing. J Biomed Biotechnol 2012; 2012: 798–924.
9. Stefanidou S, Gerodimos C, Benos A, et al. Clinical expression and course in patients with late onset systemic lupus erythematosus. Hippokratia 2013; 17: 153–156.
10. Boodhoo KD, Liu S and Zuo X. Impact of sex disparities on the clinical manifestations in patients with systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore) 2016; 95: e4272.
11. Guo L, Deshmukh H, Lu R, et al. Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population. Genes Immun 2009; 10: 531–538.
12. Abdel Galil SM, Edrees AM, Ajeeb AK, et al. Prognostic significance of platelet count in SLE patients. Platelets 2017; 28: 203–207.
13. Wang GJ. Clinical features of hematological abnormality in systemic lupus erythematosus-related hematological disorders. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2002; 10: 359–361.
14. Rahbar M, Chitsazian Z, Abdoli F, et al. Pure red cell aplasia due to antibody against erythropoietin in hemodialysis patients. *J Nephropathol* 2017; 6: 25–29.

15. Alves MT, Vilaca SS, Carvalho M, et al. Resistance of dialyzed patients to erythropoietin. *Rev Bras Hematol Hemoter* 2015; 37: 190–197.

16. Cervera R, Khamashta MA, Font J, et al. Systemic lupus erythematosus: clinical and immunologic patterns of disease expression in a cohort of 1,000 patients. The European Working Party on Systemic Lupus Erythematosus. *Medicine (Baltimore)* 1993; 72: 113–124.

17. Ortega LM, Schultz DR, Lenz O, et al. Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. *Lupus* 2010; 19: 557–574.

18. Wang SF, Chen YH, Chen DQ, et al. Mesangial proliferative lupus nephritis with podocytopathy: a special entity of lupus nephritis. *Lupus* 2018; 27: 303–311.

19. Khilji SI, Kok HK, Wong L, et al. Acute renal failure secondary to tuberculosis: a diagnostic challenge. *Case Reports in Nephrology* 2012; 2012: 3 pages.

20. Yabuuchi J, Hoshino J, Mizuno H, et al. Immunoglobulin G subclass 3 in ISN/RPL lupus nephritis classification. *Clin Nephrol* 2019; 91: 32–39.

21. He C, Mao T, Feng Y, et al. Anti-CII antibody as a novel indicator to assess disease activity in systemic lupus erythematosus. *Lupus* 2015; 24: 1370–1376.

22. Sandhu V and Quan M. SLE and serum complement: causative, concomitant or coincidental? *Open Rheumatol J* 2017; 11: 113–122.

23. Dagan R, Cleper R, Davidovits M, et al. Post-infectious glomerulonephritis in pediatric patients over two decades: severity-associated features. *Isr Med Assoc J* 2016; 18: 336–340.

24. You Y, Qin Y, Lin X, et al. Upregulated fractalkine levels in Chinese patients with lupus nephritis. *Cytokine* 2018; 104: 23–28.

25. Zhao L, Jiang Z, Jiang Y, et al. IL-22+CD4+ T-cells in patients with active systemic lupus erythematosus. *Exp Biol Med (Maywood)* 2013; 238: 193–199.

26. Im SR, Im SW, Chung HY, et al. Cell- and nuclear-penetrating anti-dsDNA autoantibodies have multiple arginines in CDR3 of VH and increase cellular level of pERK and Bcl-2 in mesangial cells. *Mol Immunol* 2015; 67: 377–387.

27. Ghirardello A, Doria A, Zampieri S, et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. *J Autoimmun* 2004; 22: 235–240.

28. Jain D, Aggarwal HK, Kaverappa V, et al. Anti-dsDNA negative and anti-Ro positive lupus nephritis: a report of a rare case. *Reumatismo* 2014; 65: 302–306.

29. Yang J, Xu Z, Sui M, et al. Co-positivity for anti-dsDNA, -nucleosome and -histone antibodies in lupus nephritis is indicative of high serum levels and severe nephropathy. *PLoS One* 2015; 10: e0140441.

30. Napirei M, Karsunky H, Zevnik B, et al. Features of systemic lupus erythematosus in Dnase1-deficient mice. *Nat Genet* 2000; 25: 177–181.

31. Hu CJ, Li MT, Liu J, et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. *Ann Rheum Dis* 2003; 62: 556–560.

32. Alba P, Bento L, Cuadrado MJ, et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. *Ann Rheum Dis* 2003; 62: 556–560.

33. Soltesz P, Berezcki D, Szodoray P, et al. Endothelial cell markers reflecting endothelial cell dysfunction in patients with mixed connective tissue disease. *Arthritis Res Ther* 2010; 12: R78.

34. Lokesh S, Tony K, Raghupathy SV, et al. A rare case of mixed connective tissue disease (MCTD) with intricate features of lupus, polymyositis and rheumatoid arthritis presenting with severe myositis. *J Clin Diagn Res* 2015; 9: OD05–OD07.
36. Fredi M, Cavazzana I, Quinzanini M, et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. *Lupus* 2014; 23: 672–677.

37. Pradhan V, Patwardhan M, Rajadhyaksha A, et al. Neuropsychiatric manifestations and associated autoantibodies in systemic lupus erythematosus patients from Western India. *Rheumatol Int* 2015; 35: 541–545.

38. Hirohata S, Arinuma Y, Takayama M, et al. Association of cerebrospinal fluid anti-ribosomal P protein antibodies with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. *Arthritis Res Ther* 2007; 9: R44.

39. Pasoto SG, Viana VS and Bonfa E. The clinical utility of anti-ribosomal P autoantibodies in systemic lupus erythematosus. *Expert Rev Clin Immunol* 2014; 10: 1493–1503.

40. Chindalore V, Neas B and Reichlin M. The association between anti-ribosomal P antibodies and active nephritis in systemic lupus erythematosus. *Clin Immunol Immunopathol* 1998; 87: 292–296.

41. Reichlin M and Wolfson-Reichlin M. Evidence for the participation of anti-ribosomal P antibodies in lupus nephritis. *Arthritis Rheum* 1999; 42: 2728–2729.

42. Reichlin M and Wolfson-Reichlin M. Correlations of anti-dsDNA and anti-ribosomal P autoantibodies with lupus nephritis. *Clin Immunol* 2003; 108: 69–72.

43. Awasthy N, Paul P and Mehta R. Neonatal lupus erythematosus. *Indian Pediatr* 2004; 41: 1048–1050.

44. Cui WL and Jiang H. Research progress on correlation between systemic erythematosus lupus and autoantibodies. *Int J Pediatr* 2014; 41: 277–280.